bmiMD GLP-1 Review (2026): Pricing, Coverage, and Tradeoffs

Item: bmiMD
Author: RangeYourself

bmiMD review, semaglutide compounded, $119–$159/mo ('same price at every dose'): 12-mo $119, 6-mo $129, 3-mo $149, 1-mo $159. verified 2026-09-03 in a real browser on bmimd.com/compounded-semaglutide/ — an across-the-board increase from the prior $99–$129 ladder (recorded in the 2026-08-21 pricehistory entry)., tirzepatide compounded, $179–$249/mo: 12-mo $179, 6-mo $189, 3-mo $229, 1-mo $249. verified 2026-09-03 in a real browser on bmimd.com/compounded-tirzepatide/ — an across-the-board increase from the prior $139–$179 ladder (recorded in the 2026-08-21 pricehistory entry); the tirzepatide page no longer carries the 'same price at every dose' line (the semaglutide page still does).. Low-cost compounded GLP-1 with a named 503A pharmacy and flat per-dose pricing. Independent 2026 review from RangeYourself.

By RangeYourselfLast verified 2026-09-03

Quick take

bmiMD is compounded semaglutide (glp-1) and compounded tirzepatide (glp-1/gip), once-weekly at-home injection, priced as cash-pay subscription with commitment tiers (1/3/6/12-month); 'same price at every dose'; provider visit included; subscribe & save 10%. Best for: Low-cost compounded GLP-1 with a named 503A pharmacy and flat per-dose pricing. Watch out for: The lowest advertised rate ($119/mo semaglutide, $179/mo tirzepatide) is the 12-month commitment tier; month-to-month is $159/mo semaglutide and $249/mo tirzepatide (prices rose across the board, verified 2026-09-03). The semaglutide page still says 'Same price at every dose'; the tirzepatide page no longer carries that line.

Pricing summary

Price verified: 2026-09-03 (checked against the provider’s public pricing surface)
All-in monthly cost: $119/month (medication included), 12-month plan rate
Semaglutide: Compounded, $119–$159/mo ('Same price at every dose'): 12-mo $119, 6-mo $129, 3-mo $149, 1-mo $159. Verified 2026-09-03 in a real browser on bmimd.com/compounded-semaglutide/ — an across-the-board increase from the prior $99–$129 ladder (recorded in the 2026-08-21 priceHistory entry).
Tirzepatide: Compounded, $179–$249/mo: 12-mo $179, 6-mo $189, 3-mo $229, 1-mo $249. Verified 2026-09-03 in a real browser on bmimd.com/compounded-tirzepatide/ — an across-the-board increase from the prior $139–$179 ladder (recorded in the 2026-08-21 priceHistory entry); the tirzepatide page no longer carries the 'same price at every dose' line (the semaglutide page still does).
Compounded vs brand-name: Compounded only
Insurance accepted: No insurance-billing path published (cash-pay); confirm at signup
Consult type: Async questionnaire, per the provider’s published flow
Dose-escalation pricing: Semaglutide page keeps 'Same price at every dose' (verified 2026-09-03); the tirzepatide page no longer states it. Price varies by plan length (commitment tier): best-purchasable = $119/mo semaglutide on the 12-month plan; month-to-month = $159/mo. A separate 'GLP-1 Treatment Plans' bundle page (bmimd.com/personalized-glp-1/) prices its own ladder: subscribe $149.40/$179.10/$189/$228.60 per month for 12/6/3/1-month plans (10% off one-time rates of $166/$199/$210/$254).
Refund policy: Cancel a subscription up to 48h before the monthly processing date (orders@bmimd.com); no refund for products already shipped from the fulfillment pharmacy.
States served: Select states, confirm at signup

See bmiMD pricing →

Choose bmiMD if

You want low-cost compounded semaglutide or tirzepatide with medication and provider visit included
You value a named, disclosed 503A compounding pharmacy (Precision Compounding Pharmacy) and flat 'same price at every dose'
You want the lowest rate via a 12-month commitment (or month-to-month at a higher price)
You want HSA/FSA eligibility and free shipping

Skip bmiMD if

You want a video visit, insurance billing, or a brand-name (non-compounded) GLP-1.

Contraindications and clinical notes

Standard GLP-1 contraindications per GLP-1 prescribing information (personal/family history of MTC or MEN 2). Provider retains full discretion to prescribe or decline.. Talk to a clinician about personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, or other conditions before starting any GLP-1 medication.

Verified programs that cost less than bmiMD

bmiMD’s own verified figure is $119/mo (12-month plan rate). Every program below carries a lower all-in monthly price that we verified on the provider’s own pricing page, ranked lowest first as of September 3, 2026.

1.Embody
$69/mo (limited-time promo), verified August 21, 2026
See pricing →
2.Strut Health
$99/mo (sublingual/oral starting price), verified August 21, 2026
See pricing →
3.Trimi
$99/mo (annual-plan rate), verified August 21, 2026
See pricing →
4.HealthRX
$99/mo (12-month plan rate), verified August 21, 2026
See pricing →

Prices are each provider’s own published all-in monthly figure at the plan term shown, verified on the date listed. RangeYourself may earn a commission from some programs; that can only break an exact tie between verified equals and never changes the price order.

How bmiMD compares

Frequently asked questions

How much does bmiMD cost per month?

bmiMD's lowest verified rate is $119/month with compounded medication included, and that figure is its 12-month plan rate rather than a month-to-month price. Semaglutide: Compounded, $119–$159/mo ('Same price at every dose'): 12-mo $119, 6-mo $129, 3-mo $149, 1-mo $159. Verified 2026-09-03 in a real browser on bmimd.com/compounded-semaglutide/ — an across-the-board increase from the prior $99–$129 ladder (recorded in the 2026-08-21 priceHistory entry).; tirzepatide: Compounded, $179–$249/mo: 12-mo $179, 6-mo $189, 3-mo $229, 1-mo $249. Verified 2026-09-03 in a real browser on bmimd.com/compounded-tirzepatide/ — an across-the-board increase from the prior $139–$179 ladder (recorded in the 2026-08-21 priceHistory entry); the tirzepatide page no longer carries the 'same price at every dose' line (the semaglutide page still does).. Semaglutide page keeps 'Same price at every dose' (verified 2026-09-03); the tirzepatide page no longer states it. Price varies by plan length (commitment tier): best-purchasable = $119/mo semaglutide on the 12-month plan; month-to-month = $159/mo. A separate 'GLP-1 Treatment Plans' bundle page (bmimd.com/personalized-glp-1/) prices its own ladder: subscribe $149.40/$179.10/$189/$228.60 per month for 12/6/3/1-month plans (10% off one-time rates of $166/$199/$210/$254).

Does bmiMD accept insurance?

bmiMD publishes cash-pay prices and we found no insurance-billing path on its own site. Where a provider's own FAQ leaves the door open, the answer sits inside its intake flow, which we do not enter, so confirm at signup rather than treating this as settled. If you want insurance-billed brand-name GLP-1, see our list of GLP-1 programs that accept insurance.

What states does bmiMD serve?

bmiMD serves Select states, confirm at signup.

Is bmiMD compounded or brand-name?

bmiMD prescribes compounded semaglutide and tirzepatide via state-licensed 503A pharmacies or 503B outsourcing facilities. Compounded medication is not individually FDA-approved. The shortage-era compounding pathway ended after the FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so compounding now proceeds under the ordinary rules for individual patients.

What's the catch with bmiMD?

The lowest advertised rate ($119/mo semaglutide, $179/mo tirzepatide) is the 12-month commitment tier; month-to-month is $159/mo semaglutide and $249/mo tirzepatide (prices rose across the board, verified 2026-09-03). The semaglutide page still says 'Same price at every dose'; the tirzepatide page no longer carries that line. Avoid if: you want a video visit, insurance billing, or a brand-name (non-compounded) glp-1.

What the records show

bmiMD's Trustpilot average is strong, while its BBB grade is more middling, again, two independent records that don't fully agree.

Trustpilot: 4.4★ (868 reviews) via Trustpilot, checked 2026-07-24

BBB: C+ rating (not accredited), BBB profile, checked 2026-07-24

38 complaints filed; failure to respond to 1.

Independently observed third-party data, not our own editorial score. Full methodology: GLP-1 Provider Reliability Report.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

About these products

These are compounded preparations, not FDA-approved for anti-aging or longevity indications, and a prescription from a licensed clinician is required. Compounding pharmacies are not individually reviewed by the FDA for the safety or effectiveness of a specific compounded product. We rank and describe these programs on price and access only, never on efficacy, outcomes, or benefit claims, and we do not repeat a provider’s own marketing claims as independently verified fact.

NAD+: NAD+ is not an FDA-approved drug, and its compounding status is not settled in its favor. In a warning letter to GenoGenix LLC dated January 20, 2026 (WL#718739), the FDA stated that NAD+ is not eligible for compounding by a 503B outsourcing facility. We could not identify a clear 503A pathway for it either: it has no USP monograph and is not a component of an approved drug. A Class I recall of an NAD+ injectable over endotoxin contamination is also on the record. We rank the programs on this page on published price only, and price is not a safety, quality, or eligibility signal here, confirm sourcing, the dispensing pharmacy, and any state restrictions directly with the provider before purchase, and discuss it with a prescribing clinician.

Sermorelin: not currently marketed as an FDA-approved product; it is compounded by licensed pharmacies for individual patients.

These peptide and longevity products are not identical to, and are never described here as generic or equivalent to, any FDA-approved drug, and unlike compounded GLP-1 medication most of them have no FDA-approved counterpart at all. State availability varies by provider and by product, several programs listed here disclose per-state restrictions; confirm eligibility in your state before purchase. RangeYourself does not provide medical advice and does not guarantee a prescription.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers verified on 2026-09-03 and may change.